Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Cell Biol ; 19(9): 5872-81, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10454534

ABSTRACT

While p53 activity is critical for a DNA damage-induced G(1) checkpoint, its role in the G(2) checkpoint has not been compelling because cells lacking p53 retain the ability to arrest in G(2) following DNA damage. Comparison between normal human foreskin fibroblasts (HFFs) and HFFs in which p53 was eliminated by transduction with human papillomavirus type 16 E6 showed that treatment with adriamycin initiated arrest in G(2) with active cyclin B/CDC2 kinase, regardless of p53 status. Both E6-transduced HFFs and control (LXSN)-transduced cells maintained a prolonged arrest in G(2); however cells with functional p53 extinguished cyclin B-associated kinase activity. Down regulation was mediated by p53-dependent transcriptional repression of the CDC2 and cyclin B promoters. In contrast, cells lacking p53 showed a prolonged G(2) arrest despite high levels of cyclin B/CDC2 kinase activity, at least some of which translocated into the nucleus. Furthermore, the G(2) checkpoint became attenuated as p53-deficient cells aged in culture. Thus, at late passage, E6-transduced HFFs entered mitosis following DNA damage, whereas the age-matched parental HFFs sustained a G(2) arrest. These results indicate that normal cells have p53-independent pathways to maintain DNA damage-induced G(2) arrest, which may be augmented by p53-dependent functions, and that cells lacking p53 are at greater risk of losing the pathway that protects against aneuploidy.


Subject(s)
G2 Phase/physiology , Animals , Antineoplastic Agents/pharmacology , CDC2 Protein Kinase/genetics , CDC2 Protein Kinase/metabolism , Cells, Cultured , Cyclin B/genetics , Cyclin B/metabolism , DNA Damage , Down-Regulation , Doxorubicin/pharmacology , Fibroblasts/cytology , Fibroblasts/drug effects , Fibroblasts/metabolism , G2 Phase/drug effects , G2 Phase/genetics , Genes, p53 , Humans , Male , Mice , Mice, Knockout , Papillomaviridae/genetics , Subcellular Fractions/metabolism , Transformation, Genetic
2.
Oncogene ; 13(9): 1983-90, 1996 Nov 07.
Article in English | MEDLINE | ID: mdl-8934545

ABSTRACT

The retinoids are reported to reduce second primary aerodigestive tract tumors in patients with prior lung or head and neck carcinomas. Yet, the optimal retinoid useful for chemoprevention and those mechanisms linked to this chemoprevention are not identified. This study reports an in vitro model for carcinogen-induced transformation of immortalized human bronchial epithelial (BEAS-2B) cells that was adapted to study the anti-carcinogenic effects of all-trans-retinoic acid (RA). Following exposure to carcinogens: cigarette smoke condensate (CSC) or N-nitrosamine-4-(methylnitrosamino)-1-(3 pyridyl)-1-butanone (NNK), BEAS-2B cells exhibited evidence of transformation. This included an increased anchorage independent growth or acquired ability to form tumors in athymic mice. This transformation was inhibited by RA as demonstrated by a lack of augmented anchorage independent growth or tumor formation in athymic mice for the cells treated with RA. The BEAS-2B cells transformed by NNK exhibited an increase in cyclin E expression which was associated with an increase in the cyclin E-Cdk2 kinase activity. Over-expression of human cyclin E by transfection shows cyclin E enhances the basal clonal growth of BEAS-2B cells. In both the parental and transformed BEAS-2B cells, RA down-regulated cyclin E protein levels which was associated with an inhibition of growth and an accumulation of cells in G1. The data reported here suggest the decline of cyclin E expression represents a potential mechanism for the RA-induced growth suppression which is linked to the anti-carcinogenic effects of RA. Thus, this study reports the adaption of an in vitro model of lung carcinogenesis suitable to test the activity of chemoprevention agents.


Subject(s)
Bronchi/cytology , CDC2-CDC28 Kinases , Cyclins/metabolism , Down-Regulation , Tretinoin/pharmacology , Adenoviridae/genetics , Animals , Bronchi/drug effects , Bronchi/virology , Cell Cycle/drug effects , Cell Division/drug effects , Cell Transformation, Neoplastic , Cells, Cultured , Cyclin-Dependent Kinase 2 , Cyclin-Dependent Kinases/drug effects , Cyclin-Dependent Kinases/metabolism , Cyclins/drug effects , Cyclins/genetics , Drug Evaluation/methods , Enzyme Activation/drug effects , Epithelial Cells , Humans , Mice , Models, Biological , Nitrosamines/toxicity , Protein Serine-Threonine Kinases/drug effects , Protein Serine-Threonine Kinases/metabolism , Rabbits , Simian virus 40/genetics , Smoke , Transfection
3.
Genomics ; 26(2): 327-33, 1995 Mar 20.
Article in English | MEDLINE | ID: mdl-7601459

ABSTRACT

The PML gene located on chromosome band 15q22 is involved with the RAR alpha locus (17q21) in a balanced reciprocal translocation uniquely observed in acute promyelocytic leukemia. Physical mapping studies by pulsed-field gel electrophoresis revealed that the PML gene is flanked by two CpG islands that are separated by a variable distance in normal individuals. Several lines of evidence demonstrate that this is the consequence of a large insertion/deletion polymorphism linked to the PML locus: (1) overlapping fragments obtained with a variety of rare-cutting restriction enzymes demonstrated the same variability in distance between the flanking CpG islands; (2) mapping with restriction enzymes insensitive to CpG methylation confirmed that the findings were not a consequence of variable methylation of CpG dinucleotides; (3) the polymorphism followed a Mendelian inheritance pattern. This polymorphism is localized 3' to the PML locus. There are five common alleles, described on the basis of BssHII fragments, ranging from 220 to 350 kb with increments of approximately 30 kb between alleles. Both heterozygous (61%) and homozygous (39%) patterns were observed in normal individuals. Megabase-scale insertion/deletion restriction fragment length polymorphisms are very rare and have been described initially in the context of multigene families. Such structures have been also reported as likely regions of genetic instability. High-resolution restriction mapping of this particular structure linked to the PML locus is underway.


Subject(s)
Chromosomes, Human, Pair 15 , Genes , Neoplasm Proteins , Nuclear Proteins , Polymorphism, Restriction Fragment Length , Transcription Factors/genetics , Alleles , Chromosomes, Human, Pair 17 , Deoxyribonucleases, Type II Site-Specific , Electrophoresis, Gel, Pulsed-Field , Genetic Linkage , Humans , Leukemia, Promyelocytic, Acute/genetics , Leukemia, Promyelocytic, Acute/pathology , Promyelocytic Leukemia Protein , Receptors, Retinoic Acid/genetics , Reference Values , Repetitive Sequences, Nucleic Acid , Retinoic Acid Receptor alpha , Sequence Deletion , Translocation, Genetic , Tumor Cells, Cultured , Tumor Suppressor Proteins
4.
J Cell Biochem ; 50(4): 441-52, 1992 Dec.
Article in English | MEDLINE | ID: mdl-1469074

ABSTRACT

Urokinase (u-PA) proteolytically cleaves both human plasma (pFn) and cellular (cFn) dimeric fibronectin (M(r) 440,000) into four major polypeptides of approximately M(r) 210,000, 200,000, 25,000, and 6,000. Amino acid sequence analysis of the polypeptide fragments indicated that the enzymatic cleavage of Fn occurs at two sites: 1) between an arginine/alanine peptide bond located C-terminal to residue 259; this cleavage liberates the N-terminal M(r) 25,000 fragment and the M(r) 210,000 and M(r) 200,000 polypeptides derived from the A and B chains of Fn, respectively; and 2) between an arginine/threonine peptide bond located C-terminal to residue 2,299, thereby yielding an M(r) 6,000 dimeric fragment containing the C-terminal interchain disulfide bonds. Predigestion of Fn with u-PA increased the molecule's vulnerability to further attack by the enzymes plasmin and cathepsin D. These data provide further biochemical evidence for the proteolytic cleavage of fibronectin by plasminogen activators and substantiate that u-PA digestion of Fn may be an initial event in the local degradation of the extracellular matrix by malignant cells, possessing elevated levels of these enzymes.


Subject(s)
Fibronectins/metabolism , Urokinase-Type Plasminogen Activator/metabolism , Amino Acid Sequence , Binding Sites , Blotting, Western , Cathepsin D/metabolism , Chromatography, High Pressure Liquid , Disulfides/metabolism , Fibrinolysin/metabolism , Fibroblasts/chemistry , Humans , Macromolecular Substances , Male , Molecular Sequence Data , Molecular Weight , Peptide Fragments/chemistry , Peptide Fragments/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...